Medical Informatics for Auto-immune Diseases Market Size (2024 – 2030)

The global medical informatics for auto-immune diseases market was valued at USD 2.5 billion and is projected to reach a market size of USD 4.01 billion by the end of 2030. Over the forecast period of 2024–2030, the market is projected to grow at a CAGR of 7%. 

The use of data science and information technology to improve the knowledge, diagnosis, treatment, and management of autoimmune disorders through the analysis and interpretation of health-related data is known as medical informatics for autoimmune diseases. In the context of autoimmune disorders, this field is essential to improving patient outcomes, research, and healthcare delivery. Over the past decade, numerous developments have been made in this field. Electronic health records (EHR) were rapidly being adopted for advancements in the medical field and easier facilitation. Presently, with a growing focus on technological integration and telemedicine, this market has expanded significantly. In the future, with precision medicine, AI, and other research and developmental activities, this market is anticipated to witness good growth.

Key Market Insights:

Thirty percent of global data is generated by the healthcare sector; by 2025, that percentage is predicted to rise to 36 percent.

The need for health informatics specialists in India is expected to rise by 250% between 2022 and 2030, according to NASSCOM.

As of 2025, the global market for medical imaging analytics software is predicted to reach $4.26 billion.

In 2022, a global poll found that 44% of respondents were inclined to trust the use of artificial intelligence (AI) in healthcare for diagnosis and treatment.

In 2023, 87 million Americans had their private health information compromised, according to Atlas VPN. To tackle this, organizations have been enforcing stricter laws and data privacy measures with the aid of various advanced technologies.

Medical Informatics for Auto-immune Diseases Market Drivers:

An increasing emphasis on personalized medicine has been helping with the acceleration.

Over the years, the concept of personalized medicine has gained tremendous prominence. It involves an understanding of how an individual's distinct molecular and genetic makeup makes them susceptible to a particular illness. These biomarkers provide information about all the cellular activities that take place in a human cell. Accordingly, various therapies and vaccines are developed based on the genetic makeup. The management of autoimmune diseases can be made more successful overall by integrating patient-specific data, such as genetic and other omics data, to support personalized diagnosis and treatment strategies. This is made possible by medical informatics, which involves the collection of suitable data using various tools. This is a huge benefit since it facilitates early diagnosis and identification, avoiding serious complications in an individual. Various studies are being conducted in this area to broaden human understanding.

Technological advancements have been contributing to the success.

Fields like artificial intelligence, blockchain technology, machine learning, data analytics, cloud computing, big data, natural language processing (NLP), etc., play a crucial role in understanding various health informatics tools. These technologies help in gathering and analyzing vast amounts of data. Through this, various patterns, outcomes, treatments, and personalized plans can be created for various autoimmune diseases. Secondly, these technologies help with the interpretation of complex data. This provides a deeper level of understanding, enabling researchers to decode the information and conduct clinical trials accordingly. Thirdly, these tools help with protecting the privacy of the data. They store the data through various advanced security measures to prevent medical crimes. Moreover, these systems facilitate collaborative research solutions by offering a centrally located and conveniently accessible platform for exchanging data and analytical instruments. Thus, more insights are gained.

Medical Informatics for Auto-immune Diseases Market Restraints and Challenges:

Associated costs, data security, a lack of information, and unequal access are the main issues that the market is currently experiencing.

One of the biggest obstacles in this sector is affordability. Upgrading and maintaining the tools and equipment is necessary. Additionally, maintenance charges are applied. The smaller emerging firms can face difficulties with this aspect. Secondly, there is also the issue of data privacy. It is possible for private information about a patient's medical records and other genetic data to be disclosed and misused. This might lead to enormous financial losses for the company and cause damage to the patient. Besides, this can be used for the creation of viruses that pose a threat to humanity. Thirdly, the science of genetics has limited knowledge and data availability. As such, people in this field can face hurdles while trying to understand more about the diseases. Furthermore, since a lot of advanced technologies are used in this industry, many underdeveloped regions might not have all the tools available due to economic gaps. This can restrict availability in certain regions, creating hindrances to equal growth.

Medical Informatics for Auto-immune Diseases Market Opportunities:

R&D efforts are being prioritized to identify new proteins, biomarkers, and the precise genetic mutation that causes a certain disease. Many governmental schemes and investments are being dedicated to various research centers and labs to advance human knowledge. Patient awareness and involvement have benefited from integration with numerous healthcare institutions. These healthcare institutions have been focusing on telemedicine and remote consultations to increase patient outcomes and engagement. Companies in the market are prioritizing data sharing, publishing, and other collaborations with prestigious academic and research institutes. Through this move, there has been immense progress in the development of vaccines and clinical trials. Apart from this, genetic information is being integrated with medical informatics systems in many healthcare centers to create more data, leading to better clarity about autoimmune conditions.

MEDICAL INFORMATICS FOR AUTO-IMMUNE DISEASES MARKET REPORT COVERAGE:

Medical Informatics for Auto-immune Diseases Market Segmentation: By Type

• Hospital Information Systems

  • Electronic Health Record

  • Electronic Medical Record

  • Real-time Healthcare

  • Patient Engagement Solutions

  • Population Health Management

  • Others

• Pharmacy Information Systems

  • Prescription Management

  • Automated Dispensing Systems

  • Inventory Management

  • Others

• Laboratory Information Systems

• Medical Imaging Information Systems

• Radiology Information Systems

  • Monitoring Analysis Software

  • Picture Archiving and Communication Systems

  • Others

• Health Insurance Information Systems

Based on type, hospital information systems are the largest segment. A centralized database that houses, retrieves, and distributes patient health data is called a hospital information system (HIS). By handling patients and linking healthcare data, and HIS aids medical practitioners in coordinating patient treatment. Additionally, it guarantees that patient data is current and correct. As such, this is very vital for this market. Laboratory information systems are the fastest-growing category. A medical laboratory's whole operations are managed by a computer system called a Laboratory Information System (LIS). LIS systems support data management, input, processing, and archiving. Additionally, they keep records of every patient who comes into a medical lab. Because Laboratory Information Systems (LIS) effectively manage and streamline laboratory data and diagnoses, they are critical to the Medical Informatics for Autoimmune Diseases Market. By enabling the digitization of test findings, LIS guarantees the precise and prompt retrieval of diagnostic data about autoimmune disorders.

Medical Informatics for Auto-immune Diseases Market Segmentation: By End-Users

• Hospitals and Clinics

• Pharmaceutical and Biotechnology Companies

• Research Institutes and Laboratories

• Others

Hospitals and clinics are the largest in the industry based on end users. This is because of the sophisticated infrastructure and resources available on these channels that support easier testing. Some certified experts are aware of the use of various tools for diagnostic purposes. Moreover, these institutions have a lot of data with them. Hence, they have easier means to obtain the patient's consent for further research. Additionally, many patients trust these centers, which is a huge advantage as it makes the whole process easier. Aside from this, global corporations and other governmental organizations consistently provide funding to maintain the current facilities and purchase all the upgraded equipment. This helps with collaborations with pharma companies and labs, due to which more knowledge can be obtained. The pharmaceutical and biotechnology companies are the fastest-growing category. These organizations aim to develop suitable technologies that ease the lives of mankind. They are involved in conducting various trials by using various medical informatics tools. These tools are necessary for the development of vaccines and other targeted therapies. Renowned experts are present in these companies who are engaged in conducting research, surveys, and studies about autoimmune diseases. Furthermore, they have good funding from various multinational companies and the government to back up their attempts.

Medical Informatics for Auto-immune Diseases Market Segmentation: Regional Analysis

• North America

• Asia-Pacific

• Europe

• South America

• Middle East and Africa

With a roughly 34% market share in 2023, North America is the area with the largest market share. The US and Canada are the two most dominant nations in this market. This is because of the infrastructure and resources that are readily available. This covers medical equipment, diagnostic centers, and research facilities. As such, more studies and research can be easily carried out by this region. Secondly, this region has key players that are actively involved in vaccine development and technological advancements. A few of them include Epic Systems Corporation, Cerner Corporation, McKesson Corporation, and Allscripts Healthcare Solutions. These companies have a strong presence in various regions of the world. Hence, a greater amount is generated. Furthermore, due to economic growth, a greater number of investments are possible in these regions. Companies and research labs are granted various funds that support easier collaboration and milestones in this field. The fastest-growing area is Asia-Pacific, with countries like China, Japan, Singapore, and India at the top. This area makes up around 22% of the total. The healthcare system in these areas is expanding. As the economy achieves stability, more money is being made available. This involves the quicker development of diagnostic infrastructure. Many startups have come up with solutions like enhanced data privacy, wearable technologies, genomic data integration, and many more creatively and more easily. Additionally, the prevalence of autoimmune disorders is rising. This has increased the need for genetic testing techniques.

COVID-19 Impact Analysis on the Global Medical Informatics for Auto-immune Diseases Market:

On the market, the pandemic had a favorable effect. The majority of the money was directed towards applications in healthcare. Research activities were one of the main categories in this. The goal of expanding human knowledge was being pursued by several esteemed institutions, companies, and research facilities. Research was done to see if people infected with the coronavirus had a higher chance of developing autoimmune disorders. According to a research article published by the Nature Journal, the results demonstrated that in comparison to over a million age- and sex-matched uninfected persons, COVID-19 patients had a 43.0% higher risk of developing autoimmune disorders between three and 15.0 months after infection. Therefore, studies about genetic differences among individuals with autoimmune disorders who contracted the virus increased drastically. Numerous computational approaches and tools related to medical informatics have gained immense attention. Post-pandemic, the market has continued to grow owing to increased investments and research breakthroughs.

Latest Trends/ Developments:

The companies in this market are motivated to achieve a higher market share by implementing different strategies, such as acquisitions, partnerships, and investments. Companies are also spending heavily to improve existing technologies while maintaining competitive pricing. This has further resulted in increased enlargement.

Wearable devices are a recent trend that is being employed. Numerous health factors may be continuously monitored using wearable technology, including fitness trackers, smartwatches, and specialized medical wearables. Continuous monitoring of vital signs, activity levels, and certain biomarkers can give important insights regarding autoimmune disorders and the effectiveness of treatment.

Key Players:

1. IBM Watson Health

2. Philips Healthcare

3. Siemens Healthineers

4. Cerner Corporation

5. Epic Systems Corporation

6. McKesson Corporation

7. Allscripts Healthcare Solutions

8. GE Healthcare

9. Change Healthcare

10. Health Catalyst

In September 2023, Kyverna Therapeutics, a clinical-stage cell therapy company developing a new class of therapies for autoimmune diseases, and Verily, an Alphabet precision health technology company, announced a multi-year collaboration to identify novel biomarkers and innovate clinical trial design and execution. Using Verily's cutting-edge immune mapping platform (Immune Profiler), the partnership's first phase aims to identify biomarkers of treatment response in autoimmune patients receiving Kyverna's KYV-101 autologous chimeric antigen receptor (CAR) T-cell therapy, which is presently undergoing Phase 1 clinical trials in the US and Europe.

In March 2023, Regeneron Pharmaceuticals, Inc. and Sonoma Biotherapeutics, Inc. announced a partnership to leverage their respective technology platforms, scientific and clinical knowledge, and regulatory T cell (Treg) expertise in the search, development, and commercialization of innovative therapies for autoimmune diseases. Regeneron's cutting-edge VelociSuite® technologies for the identification and characterization of fully human antibodies and T cell receptors (TCRs) will be combined with Sonoma Biotherapeutics' innovative strategy for creating and producing gene-modified Treg cell therapies in this collaborative effort. 

In May 2022, an exclusive worldwide license option agreement was announced for CUG252, a potentially best-in-class Treg-selective IL-2 mutein, and other novel IL-2 muteins, with AbbVie and Cugene Inc., a clinical-stage biotechnology company focused on developing next-generation precision immunology and oncology medicines to treat cancer and autoimmune diseases.